Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTZIFHC)

• DTT Name: Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DTT Info
• Gene Name: CACNA1C

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RAUWOLFIA SERPENTINA ROOT	DMWTVAN	Discovery agent	N.A.	Approved	[1]

1 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARC029	DMYNJHI	Alzheimer disease	8A20	Phase 3	[2]

5 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CGS-27830	DM8TLY3	N. A.	N. A.	Terminated	[3]
NIGULDIPINE	DMSPWMF	N. A.	N. A.	Terminated	[1]
R-56865	DMYTI3J	Angina pectoris	BA40	Terminated	[4]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[5]
TH-9229	DMG1MPD	Reperfusion injury	ND56.Z	Terminated	[6]

12 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(-)-(R)-efonidipine	DMV6EMN	Discovery agent	N.A.	Investigative	[7]
(-)-(S)-BayK8644	DMEA9KH	Discovery agent	N.A.	Investigative	[8]
CORYNANTHEINE	DM18CUZ	Discovery agent	N.A.	Investigative	[1]
CPU-228	DMM8FUT	Cardiac failure	BD10-BD13	Investigative	[8]
CV-4093	DM983QP	Discovery agent	N.A.	Investigative	[2]
FPL64176	DMB8U4F	Discovery agent	N.A.	Investigative	[9]
MEBUDIPINE	DM0P59E	Discovery agent	N.A.	Investigative	[10]
PD-32577	DMBA15J	Discovery agent	N.A.	Investigative	[11]
SZ(+)-(S)-202-791	DM8L6ZF	Discovery agent	N.A.	Investigative	[8]
[3H](+)-cis-diltiazem	DMP6XL9	Discovery agent	N.A.	Investigative	[12]
[3H](+)-isradipine	DM7QE1J	Discovery agent	N.A.	Investigative	[13]
[3H](-)devapamil	DM0KGHP	Discovery agent	N.A.	Investigative	[14]

References

• [1] Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716.
• [2] Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406.
• [3] CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993).
• [4] Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)... J Med Chem. 1998 Oct 22;41(22):4309-16.
• [5] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159)
• [7] Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br J Pharmacol. 2004 Dec;143(8):1050-7.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529).
• [9] The calcium channel ligand FPL 64176 enhances L-type but inhibits N-type neuronal calcium currents. Neuropharmacology. 2003 Aug;45(2):281-92.
• [10] Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58.
• [11] Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52.
• [12] SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. J Pharmacol Exp Ther. 1990 Nov;255(2):600-7.
• [13] Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. J Clin Invest. 2004 May;113(10):1430-9.
• [14] Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol. 1991 Nov;40(5):734-41.